Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADCY1 | Q08828 | 13/20 | 0.79 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.72 |
| ▸ | GMNN | O75496 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20034151 | 1.00 | MAPK1 (1.00) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL23659154 | 1.00 | MAPK1 (1.00) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL29397687 | 1.00 | MAPK1 (1.00) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| Hydrochloric Acid SCHEMBL2230892 | 0.99 | MAPK1 (0.98) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| Hydrochloric Acid SCHEMBL1651080 | 0.98 | MAPK1 (0.97) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL2233173 | 0.93 | MAPK1 (0.86) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL7296382 | 0.91 | MAPK1 (0.84) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL7298484 | 0.91 | MAPK1 (0.84) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL16181423 | 0.91 | MAPK1 (0.83) | MAPK1CYP3A4TSHRNR1I2ADRA1A | |
| SCHEMBL7295088 | 0.90 | MAPK1 (0.82) | MAPK1CYP3A4TSHRNR1I2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083698-A1 | Synergistic Stimulation of Mucociliary Clearance to Treat Mucus Obstruction in Cystic Fibrosis and Other Muco-Obstructive Disorders | UNIV LELAND STANFORD JUNIOR (US) | 2026-03-26 | — | — | US | claimed |
| EP-3831933-B1 | METHOD FOR PRODUCING INTESTINAL EPITHELIAL CELLS AND INTESTINAL EPITHELIAL CELLS | FUJIFILM CORP (JP) | 2025-10-29 | — | — | EP | claimed |
| US-20250263669-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | UNIV TSINGHUA (CN) | 2025-08-21 | — | — | US | claimed |
| US-20250064859-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-02-27 | — | — | US | claimed |
| EP-4493679-A1 | HPSC-DERIVED ARTICULAR CHONDROCYTE COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | The Children's Medical Center Corporation (US) | 2025-01-22 | — | — | EP | claimed |
| WO-2024233640-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-14 | — | — | WO | claimed |
| EP-4394030-A1 | INDUCED TOTIPOTENT STEM CELLS AND PREPARATION METHOD THEREFOR | Tsinghua University (CN) | 2024-07-03 | — | — | EP | claimed |
| WO-2024064151-A1 | SYNERGISTIC STIMULATION OF MUCOCILIARY CLEARANCE TO TREAT MUCUS OBSTRUCTION IN CYSTIC FIBROSIS AND OTHER MUCO-OBSTRUCTIVE DISORDERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-28 | — | — | WO | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6919076-B1 | Conjugates of agents and transglutaminase substrate linking molecules | PERICOR SCIENCE, INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-1539930-A2 | MULTI-STEP METHOD FOR THE DIFFERENTIATION OF INSULIN POSITIVE, GLUCOSE | ES Cell International Pte Ltd. (SG) | 2005-06-15 | — | — | EP | claimed |
| US-20040110287-A1 | Multi-step method for the differentiation of insulin positive, glucose responsive cells | ES CELL INTERNATIONAL PTE LTD. | 2004-06-10 | — | — | US | claimed |
| WO-2004011621-A2 | MULTI-STEP METHOD FOR THE DIFFERENTIATION OF INSULIN POSITIVE, GLUCOSE | ES CELL INTERNATIONAL PTE LTD. (SG) | 2004-02-05 | — | — | WO | claimed |
| US-6475525-B1 | Oral preparations containing forskolin derivatives and process for producing pharmaceutical preparations | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2002-11-05 | — | — | US | claimed |
| EP-1094781-A1 | COMPOSITIONS FOR RAPID AND NON-IRRITATING TRANSDERMAL DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR FORMULATING SUCH COMPOSITIONS AND DELIVERY THEREOF | Transdermal Technologies Inc. (US) | 2001-05-02 | — | — | EP | claimed |
| CN-1292692-A | Oral preparations containing forskolin derivatives and process for producing medicinal preparations | NIPPON KAYAKU KK (JP) | 2001-04-25 | — | — | CN | claimed |
| EP-1074253-A1 | ORAL PREPARATIONS CONTAINING FORSKOLIN DERIVATIVES AND PROCESS FOR PRODUCING MEDICINAL PREPARATIONS | Nippon Kayaku Kabushiki Kaisha (JP) | 2001-02-07 | — | — | EP | claimed |
| WO-2000001351-A1 | COMPOSITIONS FOR RAPID AND NON-IRRITATING TRANSDERMAL DELIVERY OF PHARMACEUTICALLY ACTIVE AGENTS AND METHODS FOR FORMULATING SUCH COMPOSITIONS AND DELIVERY THEREOF | TRANSDERMAL TECHNOLOGIES, INC. (US) | 2000-01-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083698-A1 | Synergistic Stimulation of Mucociliary Clearance to Treat Mucus Obstruction in Cystic Fibrosis and Other Muco-Obstructive Disorders | CFTR, ADRB2, ADRA1D | MAPK1 2814/4885CYP3A4 2938/4885TSHR 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.